• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Hikma Pharmaceuticals Plc ADR (OP: HKMPY )

    50.50 -0.50 (-0.98%)
    Streaming Delayed Price Updated: 3:25 PM EDT, Sep 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 245
    Open 50.50
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 51.00
    Today's Range 50.50 - 50.50
    52wk Range 42.23 - 55.56
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
    Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. 
    Via Benzinga
    Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
    Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and... 
    Via Benzinga

    Performance

    YTD
    +11.16%
    +11.16%
    1 Month
    -5.43%
    -5.43%
    3 Month
    +1.61%
    +1.61%
    6 Month
    +3.70%
    +3.70%
    1 Year
    -3.81%
    -3.81%

    More News

    Read More
    Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
    From Guardant Health, Inc.
    Via Business Wire
    Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape
    Via Benzinga
    Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
    From Junshi Biosciences
    Via GlobeNewswire
    Friday Markets News
    Via Talk Markets
    Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)
    From Bio-Thera Solutions, Ltd.
    Via Business Wire
    Summer Friday
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.